TLR7 and tuberculosis: Apart from targeting the major metabolic pathways, there are various drugs reported to limit Leishmania infection by different mechanisms, such as using the adenosine analogues [159], anti-tuberculosis drug delamanid [122], dihydropyrimidine-based derivatives [124], TLR7 agonist [125], and curdlan [3].